Johnson & Johnson reported a strong finish to 2025, with full-year operational sales growth of 5.3% to $94.2 billion and adjusted EPS growth of 8.1% to $10.79. Q4 sales reached $24.6 billion (+7.1% operational), driven by a 21% surge in Oncology and solid 5.4% growth in MedTech, successfully offsetting the ~620 basis point headwind from STELARA biosimilars. Management declared 2025 a 'catapult year,' highlighting 28 platform products generating over $1 billion annually and a record $32 billion invested in R&D and M&A. Looking ahead, the company provided confident 2026 guidance for operational sales growth of 5.7-6.7% (midpoint $100 billion) and adjusted EPS of $11.28-$11.48, citing line of sight to double-digit growth by the end of the decade. The strategic separation of the Orthopedics business remains on track for mid-2027, further sharpening the focus on high-growth Innovative Medicine and MedTech sectors.
| Metric | Value | Change |
|---|---|---|
| Q4 Sales | $24.6 Billion | +7.1% Operational |
| FY 2025 Sales | $94.2 Billion | +5.3% Operational |
| Q4 Adjusted EPS | $2.46 | +21.5% |
| FY 2025 Adjusted EPS | $10.79 | +8.1% |
| Free Cash Flow | $19.7 Billion | On par with 2024 |
| Oncology Sales Growth | N/A | +21.0% Operational |
| MedTech Sales Growth | N/A | +5.4% Operational |
| Cash Position | $20 Billion | Strong Balance Sheet |
JNJ is aggressively positioning itself to become the undisputed leader in Oncology, targeting $50 billion in annual sales by 2030. The strategy relies on dominating multiple myeloma with a suite of assets (DARZALEX, Carvicti, Tegvyle) and expanding into solid tumors like lung and prostate cancer. Recent Phase III data showing an 83% risk reduction with Tegvyle plus Darzalex provides a formidable competitive moat and validates their 'depth of expertise' strategy.
The company is successfully executing a pivot in Immunology from the legacy STELARA franchise to next-generation assets. Tremfya has surpassed $5 billion in sales with 65.4% quarterly growth, driven by IBD indications. The anticipated 2026 launch of Icotide (oral IL-23) is framed as a 'transformational' event that will expand the market by offering a non-injectable option, signaling JNJ's intent to redefine treatment standards beyond injectables.
A major strategic realignment is underway in MedTech, characterized by the planned mid-2027 spin-off of Orthopedics and a shift toward high-growth, high-margin markets like Cardiovascular, Surgery, and Vision. Management noted that the percentage of assets in high-growth markets will jump from 50% to over 70% post-separation. This capital reallocation is focused on robotics (Ottava), pulsed field ablation (Varipulse), and premium vision care.
JNJ is deploying its significant capital ($32B in 2025) to build a 'best-in-class' pipeline through both R&D and M&A. The acquisitions of Intracellular (CAPLYTA) and Halda Therapeutics (prostate cancer) are already contributing to growth. The company's balance sheet strength ($20B cash, $19.7B FCF) allows it to invest heavily in state-of-the-art manufacturing and innovation while maintaining shareholder returns, signaling a 'growth first' mentality.
Management is actively de-risking the portfolio by diversifying revenue drivers. With 28 products generating over $1 billion annually, the company is reducing reliance on any single asset. The focus on 'six key businesses' ensures that even with the STELARA LOE impact, the company can deliver double-digit growth later in the decade, supported by a mix of mature blockbusters and new launches like Inlexo and Ribociclib.
The Talc litigation remains a significant financial and reputational risk. Despite management's aggressive defense and the exclusion of some plaintiff experts in the recent 'Albert' ruling, the special master's failure to uphold gatekeeping duties on other opinions has led to an appeal. The unpredictable nature of jury verdicts and the potential for massive settlements continue to cast a shadow over the stock, despite management's attempts to downplay the distraction.
While management claims the STELARA loss of exclusivity (LOE) is in the 'rearview mirror,' it still caused a 620 basis point headwind in 2025. Furthermore, the company faces new generic competition for OPSUMIT and SYMDEKO in 2026. The reliance on rapid uptake of new assets like Tremfya and Icotide to offset these losses creates execution risk, particularly if the Icotide launch faces delays.
Margin expansion faces significant headwinds in 2026, including $500 million in MedTech tariffs, the impact of the US government's voluntary drug pricing agreement, and a higher diluted share count due to stock price appreciation. Management only guides for 50 basis points of adjusted pretax operating margin improvement, suggesting that operating leverage may be constrained and that cost inflation is a real threat to profitability.
The MedTech segment faces competitive and procedural headwinds. While management dismissed the impact of expiring ACA subsidies, they acknowledged 'competitive pressures in PFA' (Pulsed Field Ablation) and 'VBP in China' (Volume-Based Procurement). The Electrophysiology business, while growing, is under intense competition, requiring a defensive posture from leadership to reassure investors.
The guidance for 2026 implies a deceleration in EPS growth (5.5% at the midpoint) compared to the 8.1% reported in 2025. While attributed to one-time items and investments, this slowdown may disappoint investors expecting the 'catapult' momentum to translate immediately into higher double-digit earnings growth.
Overall: Management displayed a highly confident and aggressive demeanor throughout the call, frequently using superlatives such as 'catapult,' 'unrivaled,' and 'unmatched' to describe the company's portfolio and pipeline. The tone shifted to a defensive and combative posture only when addressing Talc litigation and competitive pressures in Electrophysiology, where executives emphasized resilience and a refusal to 'roll over.' The prepared remarks were assertive about future growth, while the Q&A session revealed a deep command of operational details and a willingness to challenge analyst premises regarding market headwinds.
Confidence: HIGH - Management provided specific, granular guidance for 2026 and detailed long-term targets (e.g., $50B in Oncology by 2030). The language was decisive regarding pipeline success, market share gains, and the company's ability to absorb macro headwinds like tariffs and litigation.
5.7% to 6.7%
$100.5 Billion (Midpoint)
$11.28 to $11.48
~$21 Billion
Improvement of at least 50 basis points
Hedging & Uncertainty: Management generally used strong, definitive language ('catapult,' 'exactly what it was,' 'unrivaled') to describe past performance and future potential. However, specific hedging appeared around litigation ('no legal import until the judge actually accepts,' 'we will appeal') and macro factors ('if you do the math,' 'anticipate'). The phrase 'line of sight' serves as a temporal hedge, indicating confidence in the medium-to-long term without guaranteeing immediate quarterly execution. They also hedged on the exact impact of the Orthopedics separation, stating they are 'making good progress' rather than confirming a definitive date.
We have line of sight to double-digit growth by the end of the decade. - Joaquin Duato, Chairman and CEO
We are not rolling over... we remain resolute and confident that our deep EP expertise... position us well to continue to drive global leadership. - Tim Schmid, Executive Vice President, Worldwide Chairman, MedTech
The decision only serves to bolster our overall litigation strategy. - Joe Wolk, CFO
This is a clean story for us, one of the cleanest stories in the entire healthcare sector. - Joaquin Duato, Chairman and CEO
We expect to see acceleration. We expect the year to be better in 2026 than it was in 2025. - Tim Schmid, Executive Vice President, Worldwide Chairman, MedTech
Analyst Sentiment: Analysts were largely congratulatory and positive, focusing on the sustainability of the 'catapult' growth and the mechanics of the pipeline. Questions were detailed, probing specific drug interactions (e.g., Tegvyle positioning) and margin mechanics, indicating a high level of engagement and acceptance of the bull case.
Management Responses: Executives were verbose and data-rich, using specific metrics to counter skepticism. They were particularly defensive regarding MedTech competition and Talc litigation, but pivoted quickly to highlight competitive advantages (e.g., CARTO mapping systems). Responses regarding the 'double-digit growth' target were rehearsed and emphatic.
Sustainability of double-digit growth targets and the specific levers (pipeline vs. M&A) required to bridge the gap from current 6% growth.
MedTech market dynamics, specifically the impact of expiring ACA subsidies and competitive pressures in Electrophysiology.
Margin expansion drivers and whether the 50bps improvement is a sustainable proxy for long-term growth.
Vision Care performance and the health of the contact lens and surgical lens markets.
Multiple Myeloma franchise strategy, specifically how Tegvyle, Carvicti, and DARZALEX coexist without cannibalization.
Updates on the Inlexo launch, J-codes, and the Milvexian trial data expectations.
Talc litigation implications following the recent 'Albert' rulings and the company's appellate strategy.
Johnson & Johnson has successfully navigated the STELARA loss of exclusivity and is entering a new era of accelerated growth driven by a dominant Oncology franchise and a revitalized MedTech segment. The company's transformation strategy—shedding lower-growth Orthopedics and doubling down on high-growth Innovation and Tech—is yielding tangible results, with 28 billion-dollar products providing a resilient base. The 2026 guidance for ~$100B in sales and solid EPS growth underscores the company's operating leverage and ability to absorb macro headwinds like tariffs. While Talc litigation remains an overhang, the fundamental business momentum is robust, supported by a deep pipeline and a 'clean' growth story that management argues is unique in the healthcare sector. The path to double-digit growth by the decade's end appears credible given the current clinical data and market positioning.
Management expects a $500 million impact from MedTech tariffs in 2026, significantly higher than in 2025, which will be absorbed by operational efficiencies.
The recently announced voluntary agreement with the US government to lower drug costs will impact 2026 financial results, though management has incorporated this into guidance.
Volume-Based Procurement (VBP) in China continues to pressure pricing and margins in both MedTech and Pharma, and is factored into the 2026 outlook.
The FDA offered an unsolicited Priority Review Voucher for the MAJESTIQ-3 multiple myeloma study, indicating a supportive regulatory environment for key assets.